20 Years After First FDA Filing, Gepirone Finally Approaches Depression Market
Executive Summary
Private drug developer Fabre-Kramer is expecting approval for its antidepressant gepirone hydrochloride in September 2023. The drug has been rejected multiple times by the FDA as a treatment for major depressive disorder.